High sensitivity measurement of CRP and disease progression in multiple sclerosis
M Soilu-Hanninen, JO Koskinen, M Laaksonen… - Neurology, 2005 - AAN Enterprises
M Soilu-Hanninen, JO Koskinen, M Laaksonen, A Hanninen, EM Lilius, M Waris
Neurology, 2005•AAN EnterprisesThe authors measured serum C-reactive protein (CRP) serially in patients with multiple
sclerosis (MS) who participated the PRISMS study using a high-sensitivity technique. CRP
values were similar in patients with MS and in healthy controls but higher during MS
relapses than in remission (p= 0.010). CRP levels were lower during treatment with high-
dose interferon beta 1a than placebo (p= 0.035) and higher during first 12 months of study in
patients who progressed by year 4 compared with stable patients (p= 0.007).
sclerosis (MS) who participated the PRISMS study using a high-sensitivity technique. CRP
values were similar in patients with MS and in healthy controls but higher during MS
relapses than in remission (p= 0.010). CRP levels were lower during treatment with high-
dose interferon beta 1a than placebo (p= 0.035) and higher during first 12 months of study in
patients who progressed by year 4 compared with stable patients (p= 0.007).
The authors measured serum C-reactive protein (CRP) serially in patients with multiple sclerosis (MS) who participated the PRISMS study using a high-sensitivity technique. CRP values were similar in patients with MS and in healthy controls but higher during MS relapses than in remission (p = 0.010). CRP levels were lower during treatment with high-dose interferon beta 1a than placebo (p = 0.035) and higher during first 12 months of study in patients who progressed by year 4 compared with stable patients (p = 0.007).
American Academy of Neurology